Sentences with phrase «targeting immune system cells»

Not exact matches

The institute, which includes over 40 laboratories and more than 300 researchers, said the research would focus on modifying a patient's own immune system T - cells to target a tumor, studying ways to boost patient response to current immunotherapy drugs.

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

In reaction to infection or inflammation, immune system cells known as effector T cells (Teffs) undergo rapid changes - arming themselves and diversifying into groups that target specific diseased cells.

In this study, the SIgN team discovered for the first time that the integrity of p53 affects the production of a special cell surface protein called Major Histocompatibility Complex (MHC) class I. MHC class I molecules on the cancer cell surface serve as targets for the immune system.

One class of immunotherapeutic drugs is known as «checkpoint» inhibitors, as they target checkpoints in immune system regulation to allow the body's natural defenses, such as white blood cells, to more effectively target the cancer.

Although the group didn't identify the toxin's target, it probably causes cells to die from within by overstimulating the immune system, says immunologist Harry Hill of the University of Utah.

More importantly, it opens up exciting avenues of research to explore how restoration of p53 with drugs such as those that target ERAP1 can help to harness the immune system to recognise and destroy cancer cells.»

Researchers at Penn State have combined the two approaches by taking biodegradable polymer nanoparticles encapsulated with cancer - fighting drugs and incorporating them into immune cells to create a smart, targeted system to attack cancers of specific types.

The protein has long been considered too complex to target with a drug as it also is crucial to proper function of many immune system cells, not just B cells gone bad.

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

The researchers found that HIV spiked into semen was more successful than the virus alone at infecting T cells and macrophages (immune system cells that are believed to be the infection's initial targets in the body).

EMD Serono, Kirschbaum says, «focuses on the development of targeted cancer therapies on three therapeutic platforms: targeting the tumor cell, the tumor environment, and the immune system.»

Although some cancers — particularly those that are rife with mutations like lung cancer or melanoma — create more tangible targets on the surface of cells for the immune system to recognize and attack, other malignancies such as prostate and pancreatic cancers have proved more intransigent.

That makes sense, Swanton says, because if the immune system targets trunk antigens, it's hitting most of the cancer cells, rather than «nipping off little branches».

BREAKING DOWN MULTIPLE SCLEROSIS Taking narrow aim at the immune system isn't enough, so researchers are looking for new treatment targets within nerve cells and even in the gut.

Joseph Wu of Stanford University, California, and his team have found that a mouse's immune system can be primed to recognise and target cancer cells by vaccinating them beforehand with stem cells.

Using the JEDI technology, Mount Sinai researchers uncovered evidence that immune cells can find cells in the brain expressing their target antigen, even in non-infected states, which provides evidence of an immune surveillance pathway within the body's central nervous system.

However, the Moffitt scientists suggest that it may be possible to target the TGF - β - miR183 - DAP12 pathway in patients with lung cancer to activate the immune system and kill cancer cells.

Unfortunately, the cells provided a multitude of new targets for HIV infection — something that didn't happen in those whose immune systems had never been exposed to the adenovirus.

The human immune system wants to produce antibodies that bind to the glycoprotein to stop infection, but the glycans block immune cells from seeing their targets and developing useful antibodies.

By manipulating the function of certain immune cells, called T cells, researchers could help restore the system's balance and create new treatments to target these diseases.

As with innate immunity, the adaptive immune system — the T cells and antibodies produced by B cells that target specific molecules on invading cells — contributes to pathology or may also fight against it.

In laboratory studies, daratumumab caused the targeted killing of CD38 - carrying tumor cells by several distinct and potent mechanisms, including some that involve the immune system.

«Targeting autophagy in tumor cells is a promising strategy to reinforce the immune system to fight cancer,» he claims.

Now, instead of our drugs targeting only diseased cells, we can target the immune system and provoke cells of the immune system to do the job for us,» said E. John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology.

«Research into basic workings of immune system points to way of improving therapies for cancer: Differences in wiring of «exhausted» and effective T cells indicate possible gene - editing targets.»

Most cells from a foreign donor, such as in transplanted organs, are targeted by the immune system, but «this one has found a way to suppress the immune system of its hosts long enough to let it be passed along,» he says.

Other vaccines in trials target the blood - cell stage, and contain a parasite protein called AMA - 1, meant to prime the body's immune system to attack it.

Genetically modified Salmonella bacteria target tumors and make the immune system extra aggressive toward cancer cells.

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

Researchers in the Departments of Biomedicine and Nephrology at the University Hospital and the University of Basel have discovered that the immune system uses a molecular biological clock to target intolerant T cells during their maturation process.

The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests «we are finally poised to deliver curative therapies to cancer patients,» researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.

In this way, the patient's newly educated immune system would then target and kill any future cells that show the same antigens — the real pancreatic cancer cells.

The trouble is that the virus targets not only the lymphocyte cells, which include T cells — a key component of the body's immune system helping to fight diseases — but also other immune system cells.

An international research team headed by the rheumatologist Dr Andreas Ramming at Friedrich - Alexander - Universität Erlangen - Nürnberg (FAU) has now managed to identify an immune system cell type that can be used in a targeted attempt to control the inflammatory response in arthritis patients.

This study is the first to selectively target ILCs in the presence of an intact immune system, and these findings suggest that under normal conditions, ILCs play a critical role in dampening the anti-bacterial T - cell response using MHCII.

«These inhibitors not only target cancer cells but may also have a negative impact on the immune system and NK cells.

Two types of vaccines were used for the study: one constructed with genetically engineered DNA molecules that teach immune system cells to recognize premalignant cells expressing HPV16 E7 proteins, and one that is a non-infectious, engineered virus that targets and kills precancerous cells marked by HPV16 and HPV18 E6 and E7 proteins.

Checkpoint inhibitors are monoclonal antibodies that target certain proteins that downregulate the immune system, such as programmed cell death protein 1 (PD - 1), programmed death - ligand 1 (PD - L1) and cytotoxic T - lymphocyte antigen 4 (CTLA - 4).

The researchers found that Zika targeted two specific cell types in mice: spermatogonia, which make sperm, and Sertoli cells, which are involved in helping sperm develop and sheltering them from the blood and immune system, building what's called the blood - testis barrier.

TIM - 3 is known to play a critical role in regulating the immune system, suggesting that it may be possible to target TIM - 3 on dendritic cells in order to activate T cells.

In an article published in the January issue of Cancer Cell, the researchers describe how a new type of immunotherapy drug targeting the protein TIM - 3 works to stimulate the immune system.

New drugs that activate the immune system to target cancer cells have improved the lives of many patients with cancer.

Whereas traditional MS medications target the immune system's T - cells, ocrelizumab focuses on destroying the system's B - cells, which fuel the brain inflammation that causes the disease to worsen.

This technique uses a drug that targets the reservoir cells and activates the virus which then allows the immune system to find these cell using the activated virus as a landmark.

Because of the work of several other collaborators, Haughey says, his team knew that some sort of inflammation - promoting molecule was released from brain and targeted to the liver after brain injury to send immune system cells to the damaged area, but the identity of this go - between had been elusive for years.

The other end, known as the constant region, binds to receptors on the surface of cells that can direct the immune system to respond in a variety of ways, all in the hopes of eliminating the target on the variable end of the antibody.

Once activated, the circuit expresses proteins designed to direct the immune system to target the tumor cells, including surface T cell engagers, which direct T cells to kill the cells.

Certain molecules on tumors can serve as targets for attack by cells of the immune system.

Durvalumab and tremelimumab are drugs in clinical development that block the PD - 1 / PD - L1 and CTLA - 4 pathways, respectively, and function to restimulate the immune system to target tumor cells.